<?xml version="1.0" encoding="UTF-8"?><rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" version="2.0" xmlns:media="http://search.yahoo.com/mrss/"><channel><title><![CDATA[The Globe and Mail]]></title><link>https://www.theglobeandmail.com</link><atom:link href="https://www.theglobeandmail.com/arc/outboundfeeds/rss/author/avalyear/" rel="self" type="application/rss+xml"/><description><![CDATA[The Globe and Mail News Feed]]></description><lastBuildDate>Fri, 05 Jun 2026 07:00:41 +0000</lastBuildDate><language>en-ca</language><copyright>Copyright 2024 The Globe and Mail Inc. All rights reserved.</copyright><ttl>1</ttl><sy:updatePeriod>hourly</sy:updatePeriod><sy:updateFrequency>1</sy:updateFrequency><image><url>https://www.theglobeandmail.com/legacy/static/mobile.flag.rss.png</url><title>The Globe and Mail</title><link>https://www.theglobeandmail.com</link></image><item><title><![CDATA[Generic semaglutide is now available in Canada. Where is the medication available and is it actually cheaper?]]></title><link>https://www.theglobeandmail.com/canada/article-generic-semaglutide-ozempic-canada-availability-price-insurance/</link><guid isPermaLink="true">https://www.theglobeandmail.com/canada/article-generic-semaglutide-ozempic-canada-availability-price-insurance/</guid><dc:creator><![CDATA[Arisa Valyear, Globe Staff]]></dc:creator><description><![CDATA[Demand is high for generic versions of Ozempic, currently the best-selling drug in Canada]]></description><pubDate>Thu, 04 Jun 2026 17:37:00 +0000</pubDate><content:encoded><![CDATA[<img src="https://www.theglobeandmail.com/resizer/v2/E6MDUALYFZFVPLGJQTZ5PEJMOA.jpg?auth=3637b84c71bd4701bac0fa9056b4f7343bef1740d51a70394834646dd3db3bab&smart=true&width=8195&height=5466" alt="Generic semaglutide hit pharmacy shelves in Canada in May." height="5466" width="8195"/>]]></content:encoded><media:content url="https://www.theglobeandmail.com/resizer/v2/E6MDUALYFZFVPLGJQTZ5PEJMOA.jpg?auth=3637b84c71bd4701bac0fa9056b4f7343bef1740d51a70394834646dd3db3bab&amp;smart=true&amp;width=8195&amp;height=5466" type="image/jpeg" height="5466" width="8195"><media:description type="plain"><![CDATA[(FILES) This photograph taken on February 23, 2023, in Paris, shows the anti-diabetic medication "Ozempic" (semaglutide), one of two flagship treatments made by Danish pharmaceutical company "Novo Nordisk". Shares in Danish pharmaceuticals giant Novo Nordisk soared on May 6, 2026 after the firm, battling fierce competition for anti-obesity treatments, reported a 67 percent jump in first quarter net profit and raised 2026 forecasts. (Photo by JOEL SAGET / AFP via Getty Images)]]></media:description><media:credit role="author" scheme="urn:ebu">JOEL SAGET</media:credit></media:content></item></channel></rss>